Dr. David Vaillancourt leads international study demonstrating that a non-invasive, automated MRI method can pinpoint various types of Parkinson’s disease and Parkinson’s-like syndromes.
Award will jumpstart new Parkinson’s disease research projects.
Collaborators from the Fixel Institute and MBI will pilot a novel, low-cost intervention to improve Parkinson’s symptoms.
In the laboratory of David Vaillancourt, Ph.D., researchers are applying a groundbreaking, noninvasive imaging biomarker they identified to discover better diagnostics and treatment of Parkinson’s disease.
A team led by Cara Croft, Ph.D., has demonstrated a novel method to model Alzheimer’s disease and Parkinson’s disease pathologies and seek potential therapeutic targets. Learn more:
See media highlights stemming from Jan. 18’s Norman Fixel Institute for Neurological Diseases at UF Health gift announcement.
Funds will help launch institute at UF Health for Parkinson’s and other neurodegenerative diseases.
A review by Dr. David Vaillancourt, a member of the MBI’s executive committee, was recently featured on the cover of the journal Movement Disorders.
Study demonstrates that additional proteins misfold in the presence of neurodegenerative disease pathologies.
In a recent editorial in JAMA Neurology, a group of neurologists at at The Fixel Center for Neurological Diseases at UF Health discuss medication trends for Parkinson’s disease dementia.